MX2018004547A - Nuevos anticuerpos fv multivalentes. - Google Patents

Nuevos anticuerpos fv multivalentes.

Info

Publication number
MX2018004547A
MX2018004547A MX2018004547A MX2018004547A MX2018004547A MX 2018004547 A MX2018004547 A MX 2018004547A MX 2018004547 A MX2018004547 A MX 2018004547A MX 2018004547 A MX2018004547 A MX 2018004547A MX 2018004547 A MX2018004547 A MX 2018004547A
Authority
MX
Mexico
Prior art keywords
diabody
multivalent
antibodies
chain
scfv
Prior art date
Application number
MX2018004547A
Other languages
English (en)
Spanish (es)
Inventor
Weichel Michael
Mueller Thomas
Reusch Uwe
ELLWANGER Kristina
FUCEK Ivica
RAJKOVIC Erich
Treder Martin
Ross Thorsten
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Publication of MX2018004547A publication Critical patent/MX2018004547A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2018004547A 2015-10-13 2016-10-13 Nuevos anticuerpos fv multivalentes. MX2018004547A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15189665.1A EP3156417A1 (en) 2015-10-13 2015-10-13 Multivalent fv antibodies
PCT/EP2016/074642 WO2017064221A1 (en) 2015-10-13 2016-10-13 Multivalent fv antibodies

Publications (1)

Publication Number Publication Date
MX2018004547A true MX2018004547A (es) 2018-11-09

Family

ID=54325413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004547A MX2018004547A (es) 2015-10-13 2016-10-13 Nuevos anticuerpos fv multivalentes.

Country Status (13)

Country Link
US (1) US11572415B2 (enExample)
EP (2) EP3156417A1 (enExample)
JP (1) JP6936497B2 (enExample)
KR (1) KR20180057720A (enExample)
CN (1) CN108473577A (enExample)
AU (1) AU2016336866B2 (enExample)
BR (1) BR112018007445A2 (enExample)
CA (1) CA3001765A1 (enExample)
IL (1) IL258638B2 (enExample)
MX (1) MX2018004547A (enExample)
SG (2) SG11201803083XA (enExample)
WO (1) WO2017064221A1 (enExample)
ZA (1) ZA201802543B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44381A (fr) 2015-06-15 2019-01-23 Numab Innovation Ag Format d'anticorps hétérodimères multispécifiques
AU2018295119B2 (en) * 2017-06-25 2024-10-03 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
JP7288913B2 (ja) 2018-03-14 2023-06-08 アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク 二重特異性ｅｇｆｒ／ｃｄ１６抗原結合タンパク質
CN111527108A (zh) * 2018-03-27 2020-08-11 西雅图免疫公司 制导和导航控制蛋白的制造和使用方法
US20240132626A1 (en) * 2018-04-13 2024-04-25 Eli Lilly And Company Fab-Based Trispecific Antibodies
BR112020020828A2 (pt) * 2018-04-13 2021-01-19 Affimed Gmbh Proteínas de ligação, composições farmacêuticas, método para o tratamento ou melhoria de uma doença, para tratar e/ou prevenir uma doença, para tratar um paciente e para tratar câncer e anticorpos
US20210179734A1 (en) * 2018-04-17 2021-06-17 Invenra Inc. Trivalent trispecific antibody constructs
AU2019327155A1 (en) 2018-08-27 2021-03-18 Affimed Gmbh Cryopreserved NK cells preloaded with an antibody construct
CN115066274A (zh) * 2019-09-25 2022-09-16 斯图加特大学 三价结合分子
CN118459602A (zh) * 2019-11-06 2024-08-09 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
AU2020414409A1 (en) 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
TWI874613B (zh) * 2020-03-17 2025-03-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
CA3187272A1 (en) 2020-10-08 2022-04-14 Thorsten Ross Trispecific binders
EP4255931A1 (en) * 2020-12-03 2023-10-11 Amgen Inc. Immunoglobuline constructs with multiple binding domains
JP2024510098A (ja) * 2021-02-19 2024-03-06 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ＧＰＲＣ５ＤｘＢＣＭＡｘＣＤ３三重特異性抗体およびその使用
IL308154A (en) 2021-07-30 2023-12-01 Affimed Gmbh Double structure antibodies
IL311765A (en) * 2021-09-29 2024-05-01 Modex Therapeutics Inc Antigen-binding polypeptides, antigen-binding polypeptide complexes and methods of using them
CN114316060B (zh) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用
US20230272069A1 (en) * 2022-02-28 2023-08-31 Institute Of Hematology And Blood Diseases Hospital, Chinese Academy Of Medical Sciences Chimeric Antigen Receptor Targeting CD22 and CD19 and Application thereof
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025235413A1 (en) * 2024-05-05 2025-11-13 Duke University Compositions targeting cancer antigens and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DE69535719T2 (de) * 1994-01-07 2009-03-19 Mochida Pharmaceutical Co. Ltd. Fas-antigenbindender ligand
US5989830A (en) * 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
EP1294904A1 (en) * 2000-06-30 2003-03-26 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Heterodimeric fusion proteins
ES2276735T3 (es) * 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
AU2002364531A1 (en) * 2001-12-26 2003-07-24 Ibc Pharmaceuticals Methods of generating multispecific, multivalent agents from vh and vl domains
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
CA2657385A1 (en) * 2006-07-13 2008-01-17 Naoki Kimura Cell death inducer
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
FR2959416B1 (fr) * 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
EP2655415A4 (en) 2010-12-22 2016-03-09 Abbvie Inc THREE VARIABLE DOMAIN LINK PROTEINS AND USES THEREOF
TWI671315B (zh) * 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
ES2784631T3 (es) * 2012-12-03 2020-09-29 Novimmune Sa Anticuerpos anti-CD47 y métodos de uso de los mismos
WO2014106004A2 (en) 2012-12-28 2014-07-03 Abbvie, Inc. High-throughput system and method for identifying antibodies having specific antigen binding activities
US20150017120A1 (en) * 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
MA44381A (fr) * 2015-06-15 2019-01-23 Numab Innovation Ag Format d'anticorps hétérodimères multispécifiques

Also Published As

Publication number Publication date
AU2016336866B2 (en) 2023-05-25
SG11201803083XA (en) 2018-05-30
ZA201802543B (en) 2020-01-29
EP3362478A1 (en) 2018-08-22
IL258638B (en) 2022-12-01
CN108473577A (zh) 2018-08-31
IL258638B2 (en) 2023-04-01
AU2016336866A1 (en) 2018-05-10
EP3156417A1 (en) 2017-04-19
WO2017064221A1 (en) 2017-04-20
CA3001765A1 (en) 2017-04-20
US20190040155A1 (en) 2019-02-07
KR20180057720A (ko) 2018-05-30
BR112018007445A2 (pt) 2019-12-10
IL258638A (en) 2018-06-28
RU2018126966A3 (enExample) 2020-04-20
RU2018126966A (ru) 2020-02-10
JP2018537415A (ja) 2018-12-20
JP6936497B2 (ja) 2021-09-15
SG10202004094VA (en) 2020-05-28
US11572415B2 (en) 2023-02-07

Similar Documents

Publication Publication Date Title
MX2018004547A (es) Nuevos anticuerpos fv multivalentes.
PH12018500635A1 (en) Bispecific antibodies specific for pd1 and tim3
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
DK3638698T3 (da) Anti-TMPRSS2-antistoffer og antigenbindingsfragmenter
NZ732628A (en) Bispecific tetravalent antibodies with binding specificity for first and second egfr family members and methods of making and using thereof
BR112018015480A2 (pt) proteínas de ligação ao antígeno que se ligam a pd-l1
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
PH12017500890A1 (en) Antibody drug conjugates
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
IL291545A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
MX2018001566A (es) Construcciones de union a antigeno para moleculas diana.
AR105267A1 (es) Anticuerpos de unión a tau
PL3176181T3 (pl) Przeciwciało monoklonalne anty-CTLA4 lub jego fragment wiążący antygen, kompozycja lecznicza i zastosowanie
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
HK1218930A1 (zh) 新型多特异性结构
MX2015012540A (es) Ratón de cadena ligera común.
WO2016205427A3 (en) Binding proteins against vegf, pdgf, and/or their receptors
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
IL278244A (en) Antibodies and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates and uses thereof
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
EP3144676A4 (en) Kit comprising antibody specifically binding to complement factor b protein and antibody specifically binding to carbohydrate antigen 19-9 protein for diagnosing pancreatic cancer
WO2021041300A3 (en) Bispecific antibodies and uses thereof
WO2020023619A3 (en) Blood brain barrier selective antibodies and methods of use
AR107083A1 (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
AR118080A2 (es) Proteínas de unión a antígeno dirigidas contra el receptor